Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in: Wiener Medizinische Wochenschrift 15-16/2022

10.02.2022 | main topic

Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate

verfasst von: Klaus Berek, Claudia Paganini, Harald Hegen, Gabriel Bsteh, Astrid Grams, Michael Auer, Thomas Berger, Florian Deisenhammer, Franziska Di Pauli, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2022

Einloggen, um Zugang zu erhalten

Summary

Background

Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven.

Case presentation

We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.

Conclusion

Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.
Vorheriger Artikel Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
Nächster Artikel Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever
Literatur
1.
2.
Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365–77.CrossRefPubMed
3.
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.CrossRefPubMed
4.
Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12:697974.CrossRefPubMedPubMedCentral
5.
Guger M, Traxler G, Drabauer M, Leitner-Pohn D, Enzinger C, Leutmezer F, et al. Pregnancy outcomes in patients with multiple sclerosis exposed to natalizumab‑A retrospective analysis from the Austrian multiple sclerosis treatment registry. Front Neurol. 2020;11:676.CrossRefPubMedPubMedCentral
6.
Landi D, Marfia GA. Exposure to natalizumab during pregnancy and lactation is safe—Yes. Mult Scler. 2020;26(8):887–9.CrossRefPubMed
7.
8.
Peng A, Qiu X, Zhang L, Zhu X, He S, Lai W, et al. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. J Neurol Sci. 2019;396:202–5.CrossRefPubMed
9.
Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90(10):e823–e31.CrossRefPubMed
10.
Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology. 2018;90(10):e832–e9.CrossRefPubMed
11.
Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150.CrossRefPubMedPubMedCentral
12.
Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205.CrossRefPubMed
13.
Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5.CrossRefPubMed
14.
Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: The role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845–50.CrossRefPubMed
15.
Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5.CrossRefPubMedPubMedCentral
16.
Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63.CrossRefPubMed
17.
Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24–8.CrossRefPubMed
18.
De Las Heras V, De Andres C, Tellez N, Tintore M. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler. 2007;13(8):981–4.CrossRefPubMed
19.
Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):117–30.CrossRefPubMed
20.
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.CrossRefPubMedPubMedCentral
21.
Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–7.CrossRefPubMed
22.
Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627–34.CrossRefPubMed
23.
Gonzalez-Suarez I, Rodriguez de Antonio L, Orviz A, Moreno-Garcia S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e671.CrossRefPubMedPubMedCentral
24.
Guilloton L, Pegat A, Defrance J, Quesnel L, Barral G, Drouet A. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod. 2017;46(3):301–2.CrossRefPubMed
25.
Ciron J, Hautecoeur P, Mathis S, Neau J. Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery. Rev Neurol. 2015;172(2):165–6.CrossRefPubMed
26.
De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131(5):336–40.CrossRefPubMed
27.
O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–65.CrossRefPubMed
28.
Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis:‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–14.CrossRefPubMed
29.
Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15(2):115–27.CrossRefPubMed
30.
Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford: Oxford University Press; 1979.
31.
Robertson L. Contemporary interpretation of informed consent: autonomy and paternalism. Br J Hosp Med (Lond). 2016;77(6):358–61.CrossRef
32.
Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855–62.CrossRefPubMed
Metadaten
Titel
Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate
verfasst von
Klaus Berek
Claudia Paganini
Harald Hegen
Gabriel Bsteh
Astrid Grams
Michael Auer
Thomas Berger
Florian Deisenhammer
Franziska Di Pauli, MD, PhD
Publikationsdatum
10.02.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2022
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00913-6

Weitere Artikel der Ausgabe 15-16/2022

Wiener Medizinische Wochenschrift 15-16/2022 Zur Ausgabe

main topic

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity

main topic

Experimental laboratory biomarkers in multiple sclerosis

main topic

Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever

themenschwerpunkt

Neuer Masterstudiengang: Multiple Sklerose Management

main topic

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

main topic

Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects